PROMISE

Trial PROMISE
Cancer Type Haematological Cancers and Other Haematological
Hospital(s) Belfast City Hospital
Information

Investigation Into The Combination Of PLX2853 With Ruxolitinib In Patients With Intermediate-2 Or High Risk Myelofibrosis Not Receiving An Adequate Response With Ruxolitinib Alone

Posted in .